Industry Focus
Healthcare: Digging Into Disappointment. What Investors Need To Know About Sarepta and Gilead Sciences' "Bad News"
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:19:04
- Mas informaciones
Informações:
Sinopsis
Discussing the details behind the FDA's negative vote on Sarepta's DMD drug and Gilead Sciences' sliding hepatitis C sales.
